MARKET

SLRN

SLRN

Acelyrin
NASDAQ
2.360
-0.100
-4.07%
After Hours: 2.360 0 0.00% 17:49 05/09 EDT
OPEN
2.470
PREV CLOSE
2.460
HIGH
2.490
LOW
2.350
VOLUME
395.89K
TURNOVER
--
52 WEEK HIGH
7.25
52 WEEK LOW
1.845
MARKET CAP
238.14M
P/E (TTM)
-0.9441
1D
5D
1M
3M
1Y
5Y
1D
WEX, Acelyrin, and More Stocks See Action From Activist Investors
Barron‘s · 11h ago
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis
Barchart · 3d ago
Weekly Report: what happened at SLRN last week (0428-0502)?
Weekly Report · 5d ago
Acelyrin urges stockholders to vote for proposed merger with Alumis
TipRanks · 05/01 17:45
Press Release: ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis
Dow Jones · 05/01 17:30
Press Release: ACELYRIN Reiterates Benefits of -2-
Dow Jones · 05/01 17:30
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis
Barchart · 05/01 12:30
May 2025's Rising Stars: Three Penny Stocks To Consider
Simply Wall St · 05/01 11:05
More
About SLRN
More
ACELYRIN, INC. is a late-stage clinical biopharma company. The Company is focused on providing treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The Company has two programs in late-stage clinical development. The Company’s lead product candidate, izokibep, is being evaluated in multiple immunologic indications, including hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and uveitis. The Company is also developing Lonigutamab for the treatment of thyroid eye disease (TED), as well as developing SLRN-517 in chronic urticaria. Izokibep is an inhibitor of anti-interleukin (IL)-17A in phase III development for the treatment of psoriatic arthritis, hidradenitis suppurativa and uveitis. Lonigutamab is a subcutaneously delivered monoclonal antibody targeting IGF-1R being investigated for the treatment of TED. SLRN-517, a fully IgG1 human monoclonal antibody designed to target a distinct epitope of c-KIT.
Recently
Symbol
Price
%Change

Webull offers ACELYRIN Inc stock information, including NASDAQ: SLRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLRN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLRN stock methods without spending real money on the virtual paper trading platform.